Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 7Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Burkitt Lymphoma 2Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1

Interventions

ponatinib 1Vincristine 1Prednisone 1Methotrexate 1Imatinib Mesylate 1Dexamethasone 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) × Cytarabine × Clear all
NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Takeda

Phase 3 Active not recruiting
245 enrolled 15 charts 1 FDA
LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡